An expansion of its potentials for the Cuban medicine and abroad, undergoes the Dalmer Laboratories S.A., one of the Cuba’s exporter leaders in this field, his director, doctor Rafael Gamez explained.
With these perspectives, Gamez stood out the first plant of soft capsules builds in the country which is in the final stage of construction for the Palmex production, a product already registered which has proven its effectiveness in the treatment of the benign prostatic hyperplasia.
In addition, the scientist said that this nutritional supplement, a lipid extract made from the royal palm fruit with antioxidant properties, was subjected to a strict experimentation process which included rigorous toxicological studies with the aim to favor the registry request as natural origin medicine.
Likewise, he referred to the research advances to obtain an oral vaccine against the cholera which is in clinical trial phase and it was developed in collaboration with Finlay Institute.
The marketing opens up to third parties, beyond the National Center of Scientific Researches (CENIC) to which they belong, it is also considered by the director, who referred to the arranges with the National Center of Bio-preparations (BioCen), HeberBiotec, Center of Genetic Engineering and Biotechnology (CIGB) and the University of Havana.
Other pharmaceutical products marketed by this entity, besides the polycosanol or ppg that it is the most renowned, are the Prevenox, beneficial to the treatment of bone diseases; the Abexol, with magnificent results to treat gastric complaints; the oral and topical oleozon, the vasoactol (a vasoactive product) and the toilet soap made from the ozonized sunflower oil.
In the medical equipment profile, Dalmer S.A. develops the Diramic, a semiautomatic device to micro-continuous flow coupled to a computer for the fast microbiological diagnosis, this equipment is used in microbiology laboratories of the national health system.
An ozone generator for medical use is another equipment marketed by the entity, in keeping with the wide use of this technology in the face of suffering of angiology, neurology, ophthalmology, gastroenterology, rheumatology, otolaryngology, gyneco-obstetrics, maxillofacial and other specialties.
In March should be finish the merger of Dalmer S.A like marketing entity with the CENIC like manufacturing institution.